Roivant Sciences Ltd. (ROIV)
Pre-market:
| Previous close | 10.90 |
| Open | 10.98 |
| Bid | 11.18 x 1500 |
| Ask | 11.24 x 300 |
| Day's range | 10.90 - 11.35 |
| 52-week range | 8.06 - 13.24 |
| Volume | |
| Avg. volume | 7,064,721 |
| Market cap | 9.034B |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | 2.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
- PR Newswire
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
- GlobeNewswire
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update.Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in cash payable upon the completion of a near-term milestoneBatoclimab produced positive results in Graves’ disease with response rates meaningfully exceeding 50% in the initial cohort of an ongoing 24
